Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor Targeting
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · cited 1×
“This phenomenon was described as the EPR effect: enhanced permeability and retention effect (Maeda, 2001).”
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 3×
“Among possible mechanisms of transport to the brain are transcytosis or inhibition of an efflux system, especially P-glycoprotein (Batrakova et al., 1999; Kreuter, 2001).”
Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Calvo, P., Gouritin, B., Chacun, H., Desmaële, D., D'Angelo, J., Noel, J.-P., Georgin, D., Fattal, E., Andreux, J. P., & Couvreur, P. (2001) · Pharmaceutical Research · doi:10.1023/a:1010931127745 · Cited by 443
Self-citation
Cited by
Nanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
Self-citationTransport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715
Nance, E. A., Woodworth, G. F., Sailor, K. A., Shih, T.-Y., Xu, Q., Swaminathan, G., Xiang, D., Eberhart, C., & Hanes, J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003594 · Cited by 649
“In addition, it has been shown that NPs coated with poly(ethylene glycol) (PEG) accumulate more efficiently in the brain with a compromised BBB compared to similar uncoated NPs (8, 9), at least partly as a result of the greatly improved blood circulation time and the “stealth” nature of PEG-coated particles (10).”
BackgroundNanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Interaction of Nanoparticles with Cells
Mailänder, V., & Landfester, K. (2009) · Biomacromolecules · doi:10.1021/bm900266r · Cited by 576
Optical and MRI Multifunctional Nanoprobe for Targeting Gliomas
Veiseh, O., Sun, C., Gunn, J., Kohler, N., Gabikian, P., Lee, D., Bhattarai, N., Ellenbogen, R., Sze, R., Hallahan, A., et al. (2005) · Nano Letters · doi:10.1021/nl0502569 · Cited by 564
Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Nanoparticles—a historical perspective
KREUTER, J. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.021 · Cited by 540
Toxicity of copper oxide nanoparticles: a review study
Naz, S., Gul, A., & Zia, M. (2020) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2019.0176 · Cited by 447
Strategy for effective brain drug delivery
Alam, M. I., Beg, S., Samad, A., Baboota, S., Kohli, K., Ali, J., Ahuja, A., & Akbar, M. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.05.003 · Cited by 415
Neuroscience nanotechnology: progress, opportunities and challenges
Silva, G. A. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1827 · Cited by 382
The blood-brain barrier: structure, function and therapeutic approaches to cross it.
Tajes, M., Ramos-Fernández, E., Weng-Jiang, X., Bosch-Morató, M., Guivernau, B., Eraso-Pichot, A., Salvador, B., Fernàndez-Busquets, X., Roquer, J., & Muñoz, F. J. (2014) · Molecular Membrane Biology · doi:10.3109/09687688.2014.937468 · Cited by 380
Veiseh, O., Sun, C., Fang, C., Bhattarai, N., Gunn, J., Kievit, F., Du, K., Pullar, B., Lee, D., Ellenbogen, R. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1157 · Cited by 378
Environmental Risks of Nanotechnology: National Nanotechnology Initiative Funding, 2000−2004
Dunphy Guzmán, K. A., Taylor, M. R., & Banfield, J. F. (2006) · Environmental Science & Technology · doi:10.1021/es0515708 · Cited by 355
Applications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Circumventing Tumor Resistance to Chemotherapy by Nanotechnology
Liang, X.-J., Chen, C., Zhao, Y., & Wang, P. C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_21 · Cited by 330
Receptor-Mediated Delivery of Magnetic Nanoparticles across the Blood–Brain Barrier
Qiao, R., Jia, Q., Hüwel, S., Xia, R., Liu, T., Gao, F., Galla, H.-J., & Gao, M. (2012) · ACS Nano · doi:10.1021/nn300240p · Cited by 326
Brain cancer diagnosis and therapy with nanoplatforms☆
KOO, Y., REDDY, G., BHOJANI, M., SCHNEIDER, R., PHILBERT, M., REHEMTULLA, A., ROSS, B., & KOPELMAN, R. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.012 · Cited by 326
Aktaş, Y., Yemisci, M., Andrieux, K., Gürsoy, R. N., Alonso, M. J., Fernandez-Megia, E., Novoa-Carballal, R., Quiñoá, E., Riguera, R., Sargon, M. F., et al. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050217o · Cited by 318
Self-citationColloidal carriers and blood–brain barrier (BBB) translocation: A way to deliver drugs to the brain?
Garcia-Garcia, E., Andrieux, K., Gil, S., & Couvreur, P. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.03.031 · Cited by 314
Self-citationNanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305
Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles
Vauthier, C. (2003) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.08.005 · Cited by 283
Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer
Hamoudeh, M., Kamleh, M. A., Diab, R., & Fessi, H. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.013 · Cited by 283
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Brain uptake of thiamine-coated nanoparticles
Lockman, P. R., Oyewumi, M. O., Koziara, J. M., Roder, K. E., Mumper, R. J., & Allen, D. D. (2003) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.08.006 · Cited by 259
Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine
Esposito, E., Fantin, M., Marti, M., Drechsler, M., Paccamiccio, L., Mariani, P., Sivieri, E., Lain, F., Menegatti, E., Morari, M., et al. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9514-y · Cited by 183
Kim, H. R., Andrieux, K., Gil, S., Taverna, M., Chacun, H., Desmaële, D., Taran, F., Georgin, D., & Couvreur, P. (2007) · Biomacromolecules · doi:10.1021/bm060711a · Cited by 170
Self-citationThe Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Ambruosi, A., Khalansky, A. S., Yamamoto, H., Gelperina, S. E., Begley, D. J., & Kreuter, J. (2006) · Journal of Drug Targeting · doi:10.1080/10611860600636135 · Cited by 119
Drug targeting strategies into the brain for treating neurological diseases
Barnabas, W. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.015 · Cited by 70
Metadata
- Authors
- Brigger, I., Morizet, J., Aubert, G., Chacun, H., Terrier-Lacombe, M.-J., Couvreur, P., & Vassal, G.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2002-01
- Volume
- 303
- Issue
- 3
- Pages
- 928-936
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2014485768
- Cited by
- 234
- References
- 3
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.